Management Board

Helen Giza was appointed Chief Executive Officer effective December 6, 2022. She will continue to serve as Chief Financial Officer until a successor is appointed for this position. Helen Giza joined Fresenius Medical Care in 2019 as Chief Financial Officer and took on the additional role of Chief Transformation Officer heading the FME25 transformation program in 2021. Previously, she has been Chief Integration and Divestiture Management Officer at Takeda Pharmaceuticals since 2018. Before joining the Takeda Corporate Executive Team, she served as Chief Financial Officer of Takeda’s U.S. business unit since 2008. Prior to that she held a number of key international finance and controlling positions, amongst others at TAP Pharmaceuticals and Abbott Laboratories. Helen Giza is a U.K. Chartered Certified Accountant and holds a Master of Business Administration from the Kellogg School of Management at Northwestern University in Evanston, Illinois, USA.

CV¹

Franklin W. Maddux, MD was appointed Global Chief Medical Officer in 2019 and appointed to the Management Board on January 1, 2020. He is an expert nephrologist, IT entrepreneur and healthcare executive with more than 30 years of experience in healthcare. He joined the company in 2009 as Executive Vice President for Clinical & Scientific Affairs and Chief Medical Officer for Fresenius Medical Care North America, where he was responsible for the delivery of high-quality, value-based care for the largest integrated renal care network on the continent. His expertise and research interests have focused on quality care for chronic kidney disease patients around the world.

CV¹

Dr. Katarzyna Mazur-Hofsäß took over responsibility for the globally operating Care Enablement segment, in which Fresenius Medical Care is consolidating its healthcare products business under a global MedTech umbrella, effective January 1, 2022. Previously, she served as Chief Executive Officer for EMEA since September 1, 2018. Since 2013 she was president for EMEA at the med-tech company Zimmer Biomet. In her 25 years of professional career Katarzyna has gained extensive international experience in executive general management positions. She is a physician by educational background and holds a Ph.D. from Gdansk Medical University in Poland, as well as an MBA from the Warsaw School of Economics and the University of Minnesota.

CV¹

William Valle leads the globally operating Care Delivery segment, in which the company is combining its global healthcare services business effective January 1, 2022. Previously, he served as Chief Executive Officer for North America since February 17, 2017. Prior to that, he was Executive Vice President responsible for the dialysis service business and vascular access business of Fresenius Medical Care North America from 2014 to 2017. Bill joined Fresenius Medical Care in 2009 and has more than 30 years of experience in the dialysis industry, holding executive positions in sales, marketing and business development at several dialysis companies including Gambro Healthcare, Inc.

CV¹